Upon joining the study, you will be asked to sign an informed consent form. This document confirms your understanding of the study and your agreement to participate. It includes details about the study’s requirements and restrictions.

You will undergo an initial assessment to confirm your eligibility. This includes checking your age, weight, and medical history related to chronic kidney disease and planned cardiac surgery. Your kidney function will be evaluated using specific tests.

You will be randomly assigned to receive either the study medication, ravulizumab, or a placebo. This process is double-blind, meaning neither you nor the study team will know which treatment you receive.

If you are assigned to the ravulizumab group, you will receive the medication through an intravenous (IV) infusion. The dosage is 300 mg/30 mL, and the frequency and duration will be determined by the study protocol.

You will undergo your planned cardiac surgery. After the surgery, your kidney function and overall health will be closely monitored. This includes regular assessments to check for any signs of acute kidney injury or other adverse events.

You will have follow-up visits at specified intervals, such as days 30, 60, and 90 after the surgery. During these visits, your kidney function and general health will be evaluated. You may also be asked to complete questionnaires about your quality of life and fatigue levels.

At the end of the study period, your participation will conclude. You will have a final assessment to review your health status and any changes since the beginning of the study.